BOND-003 cohort C
77 evidence topics · 22 sources
Objective
Registry objective: complete response at any time in BCG-unresponsive CIS
Publication objective: response, safety, and tolerability
Trial-in-progress objective: confirmation of monotherapy activity
Location and study date
Centres and regions
“BOND-003 Cohort C is a single-arm, international, phase 3 study done in 41 centres (community practices and academic centres) located in North America, Asia, and Australia.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sites were selected through a study team-led qualification process that evaluated feasibility, protocol alignment, operational capabilities, and regulatory readiness, as applicable.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Countries named in the trial-in-progress report
Proportion of participants enrolled in the United States
Enrollment status of Cohort C
Latest efficacy data cutoff and median follow-up
Next data release for Cohort C
Study design
Single-arm, open-label phase 3 design with separately analyzed cohorts
Global trial in BCG-unresponsive CIS-containing and papillary disease
Response assessment schedule and central confirmation
Mandatory bladder mapping at 12 months
Design stated by the company to follow the 2018 FDA guidance
Eligibility criteria
Key inclusion criteria in the publication
“We enrolled patients aged at least 18 years with Eastern Cooperative Oncology Group performance status of 0-2 and pathologically confirmed, high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, with or without resected high-grade Ta or T1 disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Definition of BCG-unresponsive disease
Registry inclusion criteria for Cohort C
Registry key exclusion criteria
Treatment
Dose and schedule in the publication
“Patients received intravesical cretostimogene (1 × 1012 viral particles per 0·8 mL per week) as 6-week induction followed by maintenance; re-induction was permitted for persistent disease at 3 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Dose and schedule in the company annual report
Treatment courses
| Course | Schedule |
|---|---|
| Induction | “Weekly x 6” |
| Maintenance, year 1 | “Weekly x 3 Q3M for Year 1” |
| Maintenance, years 2 to 3 | “Weekly x 3 Q6M for Year 2-3” |
| Second induction | “Weekly x 6 for non-responders” |
Registry arm description: DDM pretreatment and dosing weeks
Instillation process used in Cohort C and in later studies
Study outcomes
Rationale for using complete response at any time as the primary endpoint
Primary endpoint and secondary endpoints in the trial-in-progress report
Primary endpoint in the company annual report
Registry secondary outcomes for Cohort C
“Cohort C: Duration of response (DOR)” (opens the source at this quote in a new tab)
“Cohort C:Complete Response rate at 12 months” (opens the source at this quote in a new tab)
“Cohort C and Cohort P : Cystectomy free survival” (opens the source at this quote in a new tab)
“Cohort C: Assess overall survival” (opens the source at this quote in a new tab)
Definition of complete response used in the trial
Cystectomy-free survival: definition and rationale
FDA 2018 guidance: complete response rate as the primary endpoint of a single-arm trial
FDA 2018 guidance: confidence interval, duration of response, and assessment at 3 months
FDA 2024 draft guidance: complete response as an interpretable single-arm endpoint
International Bladder Cancer Group 2016: single-arm designs and clinically meaningful response rates
“Single-arm designs may be relevant for the BCG-unresponsive population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the high risk of disease progression, a placebo-controlled arm is not ethical.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients with BCG-unresponsive CIS, we recommend an initial CR rate of 50% at 6 months and durable response rates of 30% at 12 months and 25% at 18 months as clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a recent FDA–AUA public workshop, some panel members felt that an initial CR rate of 40% to 50% at 6 months and a durable response rate of at least 30% for 18 to 24 months, with the lower bound of the 95% CI excluding 20%, could be clinically meaningful in the BCG-refractory CIS population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SITC and International Bladder Cancer Group 2023: complete response rate and duration in single-arm trials
“For populations with CIS, CR rate and duration are clinically meaningful end points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Random assignment in this setting may be less acceptable to patients/providers, and single-arm trial designs have been permitted by the US Food and Drug Administration (FDA)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Per FDA guidance, CR rate and duration should be benchmarked against historical agents or modern options (eg, valrubicin, pembrolizumab, gemcitabine and docetaxel, or nadofaragene firadenovec).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment in the registry
Participants enrolled, treated, and analyzed for efficacy
“115 patients were enrolled in the study and 112 received cretostimogene” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“complete response at any time was observed in 83 (75% [95% CI 66·3-83·2]) of 110 patients” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Efficacy and safety analysis populations
“The primary endpoint was centrally confirmed complete response at any time in patients who received at least one dose of cretostimogene and completed the 3-month assessment; safety was assessed in those who received at least one dose of cretostimogene.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Central confirmation, landmark and Kaplan-Meier analyses
Population labeled intention to treat for the 24-month landmark
Subgroup definitions for prior-therapy analyses
Results
Participant disposition
Treatment completion, discontinuation, and missed doses
Baseline characteristics
Demographics and disease characteristics, safety population
| Characteristic | n or value | % |
|---|---|---|
| Male | “83” | “74.1” |
| Female | “29” | “25.9” |
| Age, mean (SD), years | “72.9 (9.19)” | |
| Age, median (range), years | “74.0 (43-90)” | |
| Age under 65 years | “19” | “17.0” |
| Age 65 to under 75 years | “43” | “38.4” |
| Age 75 years or older | “50” | “44.6” |
| Prior BCG instillations, median (range) | “12 (7 – 66)” | |
| CIS with high-grade Ta/T1 | “22” | “19.6” |
| CIS alone | “90” | “80.4” |
| At least 1 prior therapy other than BCG | “53” | “47.3” |
| Serial adjuvant chemotherapy | “34” | “30.4” |
| Systemic immunotherapy | “7” | “6.3” |
Race, age group, and prior therapy summary
Second-line and prior intervening chemotherapy subgroups
Efficacy results
Primary endpoint: complete response at any time, June 23, 2025 cutoff
Complete response at 12 and 24 months, June 23, 2025 cutoff
| Landmark | CR rate (95% CI) | Participants in CR | CR by Kaplan-Meier estimate (95% CI) |
|---|---|---|---|
| 12 months | “46.4% (36.9, 56.1)” | “51 out of 110 patients” | “50.7% (40.9, 59.8)” |
| 24 months | “41.8% (32.5, 51.6)” | “46 out of 110” | “42.4% (32.7, 51.7)” |
Complete response at 12 months: confidence interval reported in later presentations
Duration of response, June 23, 2025 cutoff
Duration of response rates attributed to the June 23, 2025 cutoff in September 2025
Progression to muscle-invasive disease
Radical cystectomy: timing and pathologic stage
| Measure | Value |
|---|---|
| Cystectomy any time after first recurrence, n (%) | “18 (16.4%)” |
| Cystectomy within the first year of recurrence, n (%) | “17 (15.5%)” |
| Weeks from recurrence or progression to cystectomy, median (Q1, Q3) | “20.0 (14.4, 26.7)” |
| Stage T0, n (%) | “1 (0.9)” |
| Stage CIS, n (%) | “9 (8.2)” |
| Stage HG Ta, n (%) | “1 (0.9)” |
| Stage T1, n (%) | “4 (3.6)” |
| Stage T2A, n (%) | “1 (0.9)” |
| Stage T2B, n (%) | “1 (0.9)” |
| Stage N2, n (%) | “1 (0.9)” |
| Participants with T0 or NMIBC at cystectomy | “15/18 (83.3%) were T0 or NMIBC” |
Cystectomy-free and progression-free rates at 24 months in a 2026 translational presentation
Complete response in second-line and prior intervening chemotherapy subgroups
Exploratory urinary tumor DNA analysis
Complete response and duration of response at the September 30, 2024 cutoff
Complete response at 24 months and duration of response at the March 14, 2025 cutoff
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-related adverse events in the publication
“71 (63%) of 112 patients had at least one treatment-related adverse event, the most common being bladder spasm in 28 (25%) patients, pollakiuria in 25 (22%) patients, and micturition urgency in 23 (21%) patients; there were no grade 3 or 4 treatment-related adverse events and no treatment-related discontinuations or deaths.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Two (2%) patients had serious treatment-related adverse events (one non-infective cystitis and one urinary bladder haemorrhage, both grade 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related adverse events in more than 10% of participants, June 23, 2025 cutoff
| Preferred term (MedDRA v.26.1) | Any grade, n (%) | Grade 3 or higher, n (%) |
|---|---|---|
| At least 1 treatment-related adverse event | “71 (63.4%)” | “0 (0)” |
| Bladder spasm | “28 (25.0%)” | “0 (0)” |
| Pollakiuria | “25 (22.3%)” | “0 (0)” |
| Urgency | “23 (20.5%)” | “0 (0)” |
| Dysuria | “21 (18.8%)” | “0 (0)” |
| Hematuria | “15 (13.4%)” | “0 (0)” |
Severity, resolution, and serious treatment-related adverse events
Study limitations
Summary: limitations of the BOND-003 Cohort C evidence
- Design: Cohort C is a single-arm, open-label trial with no concurrent control. The FDA 2024 draft guidance states that time-to-event endpoints are “uninterpretable in a single-arm trial” and that the lack of a comparator arm makes attributing adverse events difficult; cystectomy-free survival, progression-free survival, and duration of response therefore have no comparator in this trial. The FDA 2018 guidance states that patient and provider preferences “can confound the interpretation” of cystectomy delay, particularly in single-arm trials.
- Primary endpoint: complete response at any time includes participants with persistent disease who underwent repeat induction treatment, which a later trial of another agent did not permit. At the June 23, 2025 cutoff, 83 of 110 participants (75.5%) had a complete response at any time, while landmark complete response rates were 46.4% (51 of 110) at 12 months and 41.8% (46 of 110) at 24 months.
- Populations: 115 participants were enrolled, 112 were treated and form the safety population, and 110 who completed the 3-month assessment form the efficacy population. Eligibility required pathologically confirmed BCG-unresponsive CIS, ECOG performance status 0 to 2, and medical ineligibility for, or refusal of, radical cystectomy; prior systemic treatment for bladder cancer other than checkpoint inhibitors was excluded.
- Sources: the peer-reviewed report is available only as an abstract in the sources read, and most results beyond the abstract (12-month and 24-month landmark rates, duration of response, cystectomy outcomes, subgroups) come from company-sponsored congress presentations, press releases, and filings. The trial was funded by CG Oncology. The prespecified statistical threshold for the primary endpoint was not found in the public sources read; the company states that the trial “met its primary endpoint with statistical significance”.
- Figures that differ between documents for the same June 23, 2025 cutoff: duration of response at 12 and 24 months of 64.1% and 58.3% (September 2025 press release) against 64.2% and 60.1% (2026 press release and presentation); freedom from progression to muscle-invasive disease of 96.4% (106 of 110) against 96.6%; a lower 95% confidence bound for the 12-month landmark of 36.9% against 36.8%; 24-month cystectomy-free survival of 81.3% against 85% in a translational presentation; and the second serious treatment-related adverse event named as clot retention in a 2026 company presentation and the Form 10-K and as urinary bladder haemorrhage in the publication.
- Dose: the publication states a dose of “1 × 1012 viral particles per 0·8 mL”, and the company annual report states “1x1012 VPs per milliliter”.
- Applicability: Cohort C used a five-step instillation process that included saline and DDM washes; the company states that all later studies use a two-step process. No health-related quality-of-life or patient-reported outcome results were found.